According to, on September 21, 2015, “NovoCure set the terms on its forthcoming initial public offering, saying it expects to float 7.5 million shares at $26 to $29 apiece, or $206.3 million at the midpoint of the range. NovoCure said it expects to net about $189 million from the offering, which includes an underwriters allotment for another nearly 1.9 million shares.”  For more information, please visit: